News - Novo Nordisk, Licensing


Current filters:

Novo NordiskLicensing

Popular Filters

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A


Danish insulin giant Novo Nordisk has sold full development and commercialization rights to the anti-NKG2A…

anti-NKG2AInnate PharmaLicensingMergers & AcquisitionsNovo NordiskOncologyPharmaceutical

Emisphere earns $10 million on amended deal with Novo Nordisk


USA-based Emisphere Technologies (OTCBB: EMIS) says that it has agreed with Danish insulin giant Novo…

DiabetesEmisphereLicensingNovo NordiskPharmaceuticalResearch

Mylan extends deal with Bioton to biosimilar insulins, as Actavis pulls out of JV


US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBiotechnologyBiotonDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

Novo Nordisk to acquire Taiwanese osteo/RA technology


Danish insulin giant Novo Nordisk (NOV: N) has acquired rights to technology developed by a southern…

Anti-Arthritics/RheumaticsLicensingNovo NordiskPharmaceuticalResearch

Novo Nordisk in-licenses drug delivery technology from Caisson


Danish insulin giant Novo Nordisk (NVO: N) has entered into a development and license agreement with…

Caisson BiotechHeparinexLicensingNovo NordiskPharmaceutical

Pfizer and Biocon cancel biosimilars deal


Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Back to top